Pyridoxine Responsive Seizures: Beyond Aldehyde Dehydrogenase 7A1

Roshan Koul1, Amna Alfutaisi2, Rana Abdelrahim2

  • 1Department of Neurology, Institute of Liver and Biliary Sciences, New Delhi, India.

Insights

Pyridoxine responsive seizures (PDRs) in infants often lack genetic confirmation, with many cases unidentified. Further research may reveal new genes or metabolic disorders responsible for this condition.

Area of Science:

  • Neurology
  • Genetics
  • Metabolic Disorders

Background:

  • Pyridoxine responsive seizures (PDRs) present as early-onset seizures and epileptic encephalopathy in neonates and infants.
  • Seizures in PDRs can manifest in various forms, posing diagnostic challenges.

Purpose of the Study:

  • To analyze the clinical profile of 35 children diagnosed with PDRs over a 20-year period.
  • To investigate the genetic basis and identify mutations associated with PDRs.

Main Methods:

  • A retrospective analysis of neonatal and infantile seizures responding to pyridoxine from 1998 to 2018.
  • Classification into four groups based on clinical features, lab results, and genetic testing: ALDH7A1 mutation, PLPHP mutation, no known mutation, or combination with antiepileptic drugs.

Main Results:

  • Sixteen out of 35 children had identifiable genetic mutations.
  • Four children had ALDH7A1 mutations, and 12 had recently described PLPHP mutations.
  • Nineteen children (over half) showed no genetic positivity for known mutations.

Conclusions:

  • A significant proportion of children with PDRs lack genetic confirmation of known mutations.
  • The identification of new genes or previously unknown metabolic disorders is crucial for understanding pyridoxine dependency.

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
662
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
756
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
564
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
827